Given these findings, it is not surprising that in some tumors, such as lung cancer, the concomitant loss of BRG1 and BRM occurs in a significant portion (8–10%), compared with the loss of expression of either subunit alone, which occurs in 20–30% (5, 6, 76). This evidence concerns the gene SMARCA2 and lung cancer.